Abstract: A nutritional composition that includes a milk fat globule membrane component, at least one human milk oligosaccharide, and at least one additional component chosen from the group consisting of DHA, ARA, Vitamin E, Vitamin C, and sphingomyelin. The nutritional composition is in the form of a ready-to-drink composition, a food supplement, an extruded food bar, or a solid oral dosage form. The nutritional composition is typically administered or provided to adults, children, or infants through consumption.

Abstract: A nutritional composition, typically an infant enterically administered nutritional composition, that comprises a milk fat globule membrane component, at least one human milk oligosaccharide and one additional component or a plurality of additional components where the additional component or components include DHA, ARA, Vitamin E, Vitamin C, and sphingomyelin.

Abstract: A nutritional composition that includes a milk fat globule membrane component, at least one human milk oligosaccharide, and at least one additional component chosen from the group consisting of DHA, ARA, Vitamin E, Vitamin C, and sphingomyelin. The nutritional composition is in the form of a ready-to-drink composition, a food supplement, an extruded food bar, or a solid oral dosage form. The nutritional composition is typically administered or provided to adults, children, or infants through consumption.

Abstract: A nutritional composition, typically an infant enterically administered nutritional composition, that comprises a milk fat globule membrane component, at least one human milk oligosaccharide and one additional component or a plurality of additional components where the additional component or components include DHA, ARA, Vitamin E, Vitamin C, and sphingomyelin.

Abstract: The invention relates to humanized milk. The milk is produced by a non-human transgenic mammal wherein the genome of said transgenic non-human mammal contains at least one heterologous gene encoding for a human catalytic entity and wherein the catalytic entity produces oligosaccharides and glycoconjugates that are present in the milk of said transgenic non-human mammal. An especially useful catalytic entity is human glycosyltransferases which produce oligosaccharides and glyconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter. A method of obtaining humanized milk is disclosed.

Abstract: The invention relates to transgenic non-human mammals characterized in that the genome of said mammals contain at least one heterologous gene encoding for the production of heterologous catalytic entity selected from the group consisting of enzymes and antibodies, and wherein said catalytic entity produces a second heterologous product in the milk of said mammal. Especially useful in the practice of the invention are human glycosyltransferases and transgenic sheep, goats and cows. The heterologous product includes oligosaccharides and glycoconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter.

Abstract: The invention relates to the milk of a transgenic non-human mammal. The milk is characterized in that it contains heterologous components produced as the secondary gene products of a heterologous gene contained in the genome of the transgenic non-human mammal. The heterologous gene encodes a heterologous catalytic entity such as a human enzyme selected from the group consisting of glycosyltransferases, phosphorylases, hydroxylases, peptidases and sulfotransferases. Especially useful in the practice of the invention are human glycosyltransferases. The desired heterologous components include oligosaccahrides, glycoconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter.

Abstract: An enteral nutritional product containing either bovine .kappa.-casein or human .kappa.-casein at a concentration greater than that found in human or bovine milk and sufficient to inhibit infection of mammalian cells by human rotavirus.

Abstract: The invention relates to transgenic non-human mammals characterized in that the genome of said mammals contain at least one heterologous gene encoding for the production of heterologous catalytic entity selected from the group consisting of enzymes and antibodies, and wherein said catalytic entity produces a second heterologous product in the milk of said mammal. Especially useful in the practice of the invention are human glycosyltransferases and transgenic sheep, goats and cows. The heterologous product includes oligosaccharides and glycoconjugates.